脂質異常症(Dyslipidemia)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dyslipidemia Overview 9
Therapeutics Development 10
Pipeline Products for Dyslipidemia – Overview 10
Pipeline Products for Dyslipidemia – Comparative Analysis 11
Dyslipidemia – Therapeutics under Development by Companies 12
Dyslipidemia – Therapeutics under Investigation by Universities/Institutes 16
Dyslipidemia – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Dyslipidemia – Products under Development by Companies 20
Dyslipidemia – Products under Investigation by Universities/Institutes 24
Dyslipidemia – Companies Involved in Therapeutics Development 25
Amgen Inc. 25
Arisaph Pharmaceuticals, Inc. 26
AstraZeneca PLC 27
Biocon Limited 28
Cadila Pharmaceuticals Ltd. 29
Cerenis Therapeutics Holding SA 30
Chong Kun Dang Pharmaceutical Corp. 31
CymaBay Therapeutics, Inc. 32
Daiichi Sankyo Company, Limited 33
Debiopharm International S.A. 34
Dezima Pharma BV 35
Dr. Reddy’s Laboratories Limited 36
Genfit SA 37
GlaxoSmithKline plc 38
Hanmi Pharmaceuticals, Co. Ltd. 39
High Point Pharmaceuticals, LLC 40
Intas Pharmaceuticals Ltd. 41
Jenrin Discovery, Inc. 42
JW Pharmaceutical Corporation 43
Kissei Pharmaceutical Co., Ltd. 44
Kotobuki Pharmaceutical Co., Ltd. 45
Kowa Company, Ltd. 46
Kymab Limited 47
Lipicard Technologies Limited 48
Merck & Co., Inc. 49
Nippon Chemiphar Co., Ltd. 50
Novartis AG 51
Pfizer Inc. 52
Pharmena SA 53
Piramal Enterprises Limited 54
Reviva Pharmaceuticals Inc. 55
Sanofi 56
Takeda Pharmaceutical Company Limited 57
Torrent Pharmaceuticals Limited 58
Zydus Cadila Healthcare Limited 59
Dyslipidemia – Therapeutics Assessment 60
Assessment by Monotherapy Products 60
Assessment by Combination Products 61
Assessment by Target 62
Assessment by Mechanism of Action 64
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
(ezetimibe + rosuvastatin calcium) – Drug Profile 70
(niacin + aspirin) – Drug Profile 71
(pitavastatin + valsartan) – Drug Profile 72
(rosuvastatin calcium + ezetimibe) – Drug Profile 73
(statin + niacin + aspirin) – Drug Profile 74
4655-K09 – Drug Profile 75
anacetrapib – Drug Profile 76
ARI-3037MO – Drug Profile 78
AZ-12260493 – Drug Profile 80
BioE-1115 – Drug Profile 81
bococizumab – Drug Profile 82
BSN-852 – Drug Profile 83
C-24 – Drug Profile 84
C-3 – Drug Profile 85
Centatin – Drug Profile 86
CKD-519 – Drug Profile 87
Debio-0930B – Drug Profile 88
DEZ-001 – Drug Profile 89
DF-461 – Drug Profile 90
DGAT-1 – Drug Profile 91
DRL-17822 – Drug Profile 92
evolocumab – Drug Profile 93
GFT-505 – Drug Profile 96
GSK-2041706 – Drug Profile 99
HCP-1105 – Drug Profile 100
HCP-1305 – Drug Profile 101
HDL Receptor Enhancer – Drug Profile 102
HPP-593 – Drug Profile 103
INSUPR-001 – Drug Profile 104
JD-5037 – Drug Profile 105
K-312 – Drug Profile 106
K-877 – Drug Profile 107
KT6-971 – Drug Profile 108
KTA-439 – Drug Profile 109
KY-1020 – Drug Profile 110
LP-071 – Drug Profile 111
LT-5421 – Drug Profile 112
LT-5423 – Drug Profile 113
MAT-9001 – Drug Profile 114
MBX-8025 – Drug Profile 115
MGL-3196 – Drug Profile 117
NC-2400 – Drug Profile 119
ND-630 – Drug Profile 120
ND-654 – Drug Profile 121
P-7435 – Drug Profile 122
Peroxibrate – Drug Profile 123
pitavastatin CR – Drug Profile 124
Recombinant ApoE4 for Dyslipidemia – Drug Profile 125
RP-17000 – Drug Profile 126
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes – Drug Profile 127
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes – Drug Profile 128
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia – Drug Profile 129
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia – Drug Profile 130
Small Molecules for Dyslipidemia and Hypertriglyceridemia – Drug Profile 131
Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity – Drug Profile 132
Small Molecules to Inhibit DGAT-1 for Metabolic Disorders – Drug Profile 133
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia – Drug Profile 134
SPX-100 – Drug Profile 135
SPX-8522876 – Drug Profile 136
Synthetic Peptides for Dyslipidemic and Vascular Disorders – Drug Profile 137
TAP-311 – Drug Profile 138
TRC-210258 – Drug Profile 139
TRIA-662 – Drug Profile 140
VK-0214 – Drug Profile 142
ZLN-005 – Drug Profile 143
ZLN-024 – Drug Profile 144
ZYH-7 – Drug Profile 145
ZYT-1 – Drug Profile 146
Dyslipidemia – Recent Pipeline Updates 147
Dyslipidemia – Dormant Projects 168
Dyslipidemia – Discontinued Products 175
Dyslipidemia – Product Development Milestones 180
Featured News & Press Releases 180
Appendix 194
Methodology 194
Coverage 194
Secondary Research 194
Primary Research 194
Expert Panel Validation 194
Contact Us 195
Disclaimer 195